PURAPHARM released its interim results, with a loss attributable to shareholders of HKD 21.806 million, an increase of 16.7% year-on-year
I'm PortAI, I can summarize articles.
PURAPHARM released its interim results for the period ending June 30, 2025, reporting revenue of HKD 172 million, a year-on-year decrease of 17.02%; a loss attributable to shareholders of HKD 21.806 million, a year-on-year increase of 16.7%; and a basic loss per share of HKD 0.0552. The revenue decline was mainly due to a slowdown in consumer spending in Hong Kong and intense market competition, while the group has reduced its focus on the hospital channel in the Chinese concentrated traditional Chinese medicine granule market
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments